<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2450">
  <stage>Registered</stage>
  <submitdate>4/08/2009</submitdate>
  <approvaldate>4/08/2009</approvaldate>
  <nctid>NCT00952783</nctid>
  <trial_identification>
    <studytitle>A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study</studytitle>
    <scientifictitle>A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratosis on Non-head Areas (Trunk and Extremities) Who Have Completed Day 57 in Study PEP005-020</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PEP005-031</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Actinic Keratosis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Lesion count

1 - 


Treatment: drugs: Lesion count
Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Summarize treatment area recurrence of AK lesions in the selected treatment area</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Summarize long-term safety data (incidence of adverse events in the treatment area)</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion

          -  Patient has provided informed consent documented by signing the Informed Consent Form
             (ICF) prior to any study-related procedures

          -  Patient achieved complete clearance of AK lesions (lesion count of 0) in the selected
             treatment area at the Day 57 visit in study PEP005-020</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion

          -  Concurrent participation in another research study which would involve the selected
             treatment area (except for any post-study follow-up visits for previous Peplin AK
             study)

          -  Early termination from study PEP005-020</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>98</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>Dematology on Ward - Adelaide</hospital>
    <hospital>Dermatology Institute of Victoria - Melbourne</hospital>
    <hospital>St John of God Dermatology - Subiaco</hospital>
    <postcode>5006 - Adelaide</postcode>
    <postcode>3141 - Melbourne</postcode>
    <postcode>6008 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Peplin</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to follow up patients, who have achieved complete clearance of AK
      lesions (lesion count of 0) at Day 57 in the PEP005-020 study, over a 12 month period to
      assess both recurrence of Actinic Keratosis (AK) lesions and long term safety in the selected
      treatment area.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00952783</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>